Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1941

1.

Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

Amarenco P, Goldstein LB, Messig M, O'Neill BJ, Callahan A 3rd, Sillesen H, Hennerici MG, Zivin JA, Welch KM; SPARCL Investigators.

Stroke. 2009 Jul;40(7):2486-92. doi: 10.1161/STROKEAHA.108.546135. Epub 2009 May 21.

PMID:
19461031
[PubMed - indexed for MEDLINE]
Free Article
2.

Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

Amarenco P, Goldstein LB, Callahan A 3rd, Sillesen H, Hennerici MG, O'Neill BJ, Rudolph AE, Simunovic L, Zivin JA, Welch KM; SPARCL Investigators.

Atherosclerosis. 2009 Jun;204(2):515-20. doi: 10.1016/j.atherosclerosis.2008.09.008. Epub 2008 Sep 18.

PMID:
18962621
[PubMed - indexed for MEDLINE]
3.

A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.

Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.

Clin Ther. 2008 Jun;30(6):1089-101. doi: 10.1016/j.clinthera.2008.05.017.

PMID:
18640465
[PubMed - indexed for MEDLINE]
4.

Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.

Velussi M.

Nutr Metab Cardiovasc Dis. 2002 Feb;12(1):29-35.

PMID:
12125227
[PubMed - indexed for MEDLINE]
5.

Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.

Hunninghake DB, Ballantyne CM, Maccubbin DL, Shah AK, Gumbiner B, Mitchel YB.

Clin Ther. 2003 Jun;25(6):1670-86.

PMID:
12860491
[PubMed - indexed for MEDLINE]
6.

Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.

Stender S, Schuster H, Barter P, Watkins C, Kallend D; MERCURY I Study Group.

Diabetes Obes Metab. 2005 Jul;7(4):430-8. Erratum in: Diabetes Obes Metab. 2005 Jul;7(4):460.

PMID:
15955130
[PubMed - indexed for MEDLINE]
7.

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.

Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG.

Curr Med Res Opin. 2002;18(4):220-8.

PMID:
12201623
[PubMed - indexed for MEDLINE]
8.

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.

Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators.

N Engl J Med. 2007 Sep 27;357(13):1301-10.

PMID:
17898099
[PubMed - indexed for MEDLINE]
Free Article
9.

Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

Sillesen H, Amarenco P, Hennerici MG, Callahan A, Goldstein LB, Zivin J, Messig M, Welch KM; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators.

Stroke. 2008 Dec;39(12):3297-302. doi: 10.1161/STROKEAHA.108.516450. Epub 2008 Oct 9.

PMID:
18845807
[PubMed - indexed for MEDLINE]
Free Article
10.

Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A 3rd, Hennerici M, Simunovic L, Zivin JA, Welch KM; SPARCL Investigators.

Stroke. 2007 Dec;38(12):3198-204. Epub 2007 Oct 25.

PMID:
17962589
[PubMed - indexed for MEDLINE]
Free Article
11.

Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP, Altafullah I, Ledbetter LY, MacLeod MJ, Scott R, Hennerici M, Zivin JA, Welch KM; SPARCL Investigators.

Arch Neurol. 2011 Oct;68(10):1245-51. doi: 10.1001/archneurol.2011.146. Epub 2011 Jun 13.

PMID:
21670382
[PubMed - indexed for MEDLINE]
12.

Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators.

N Engl J Med. 2005 Apr 7;352(14):1425-35. Epub 2005 Mar 8.

PMID:
15755765
[PubMed - indexed for MEDLINE]
Free Article
13.

The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study.

Kostis JB, Breazna A, Deedwania PC, LaRosa JC; Treating to New Targets Steering Committee and Investigators.

J Clin Hypertens (Greenwich). 2008 May;10(5):367-76.

PMID:
18453796
[PubMed - indexed for MEDLINE]
14.

Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.

Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; CAP Investigators.

Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.

PMID:
19167589
[PubMed - indexed for MEDLINE]
15.

High-dose atorvastatin after stroke or transient ischemic attack.

Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.

N Engl J Med. 2006 Aug 10;355(6):549-59.

PMID:
16899775
[PubMed - indexed for MEDLINE]
Free Article
16.

LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.

Jukema JW, Liem AH, Dunselman PH, van der Sloot JA, Lok DJ, Zwinderman AH.

Curr Med Res Opin. 2005 Nov;21(11):1865-74.

PMID:
16307708
[PubMed - indexed for MEDLINE]
17.

Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects.

Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JA, Seman LJ, Ferrari A, Rubenstein JJ.

Am J Cardiol. 2002 Oct 1;90(7):689-96.

PMID:
12356379
[PubMed - indexed for MEDLINE]
18.

Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience.

Velussi M, Cernigoi AM, Tortul C, Merni M.

Diabetes Nutr Metab. 1999 Dec;12(6):407-12.

PMID:
10782562
[PubMed - indexed for MEDLINE]
20.

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators.

Lancet. 2004 Aug 21-27;364(9435):685-96.

PMID:
15325833
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk